Tegoprazan(CAS: 942195-55-3)

Tegoprazan (CAS: 942195-55-3) is a crystalline compound with a molecular weight of approximately 365.4 g/mol. It is slightly soluble in water and ethanol but poorly soluble in non-polar solvents. Tegoprazan is a weak base with a pKa of about 3.8. It is chemically stable under normal conditions but can degrade under acidic or oxidative conditions.

Tegoprazan (CAS: 942195-55-3) is usually synthesized via a multi-step process involving alkylation, ring closure, and amidation reactions. Key steps include the use of tert-butyldimethylsilyl chloride as a protecting group, followed by ring formation using a condensation agent. The final amidation step uses sodium hydride and an amide to form the desired product with a high yield and selectivity.

Tegoprazan (CAS: 942195-55-3) is primarily used in the pharmaceutical industry. It is an active ingredient in proton pump inhibitors and is used to treat gastrointestinal disorders such as peptic ulcers and gastroesophageal reflux disease (GERD). While not extensively used in other industries, it may have potential applications in polymer science and as a component in biomedical devices.

When handling Tegoprazan (CAS: 942195-55-3), it is essential to wear appropriate personal protective equipment (PPE) such as gloves, safety goggles, and a lab coat. Work should be conducted in a well-ventilated environment or under a fume hood to minimize inhalation exposure. Spills should be cleaned up using absorbent materials and the area should be neutralized with an appropriate solution before disposal. Always consult the Safety Data Sheet (SDS) for detailed guidelines and emergency procedures.